What is Holmusk?
Founded in 2015 and headquartered in Singapore, Holmusk operates at the intersection of data science and clinical research. The company has developed a sophisticated Real World Evidence (RWE) platform designed to synthesize vast amounts of digital healthcare data into predictive algorithms. By focusing on neuroscience and chronic disease, Holmusk provides biopharma companies, healthcare providers, and researchers with the tools necessary to improve patient outcomes and optimize treatment efficacy. Its market position is defined by its ability to turn fragmented health data into a cohesive, actionable narrative, effectively supporting the shift toward precision medicine and value-based care delivery.
How much funding has Holmusk raised?
Holmusk has raised a total of $76.3M across 3 funding rounds:
Angel/Seed
$9.8M
Series A
$21.5M
Series B
$45M
Angel/Seed (2018): $9.8M with participation from Heritas Capital and Capikris Foundation
Series A (2020): $21.5M led by Optum Ventures, Health Catalyst Capital Management, and Heritas Capital
Series B (2023): $45M supported by Novartis, Veradigm, Health Catalyst Capital Management, Heritas Capital, and Northwell Health
Key Investors in Holmusk
Novartis
A global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions across multiple therapeutic areas.
Veradigm
An integrated data systems and services company that combines data-driven clinical insights with actionable tools to improve the quality, efficiency, and value of healthcare delivery.
Health Catalyst Capital Management
A New York-based private equity firm that invests in high-growth healthcare information technology and tech-enabled services businesses to enhance quality of care and affordability.
What's next for Holmusk?
With this major strategic investment, Holmusk is well-positioned to accelerate the expansion of its RWE platform and deepen its integration within the global healthcare ecosystem. The company is expected to focus on scaling its predictive modeling capabilities, potentially entering new therapeutic areas and enhancing its data interoperability features. As the demand for data-driven clinical insights continues to rise, Holmusk's strategic roadmap likely includes strengthening its partnerships with major pharmaceutical entities and health systems to further validate its algorithms in real-world clinical settings. This capital injection provides the necessary runway to solidify its leadership in the digital health sector and drive long-term innovation in personalized medicine.
See full Holmusk company page
